



New Day in Medicine
Новый День в Медицине

NDM



TIBBIOVIYOTDA YANGI KUN

Ilmiy referativ, marifiy-ma'naviy jurnal



AVICENNA-MED.UZ



ISSN 2181-712X.
EiSSN 2181-2187

11 (73) 2024

Сопредседатели редакционной коллегии:

**Ш. Ж. ТЕШАЕВ,
А. Ш. РЕВИШВИЛИ**

Ред. коллегия:

М.И. АБДУЛЛАЕВ
А.А. АБДУМАЖИДОВ
Р.Б. АБДУЛЛАЕВ
Л.М. АБДУЛЛАЕВА
А.Ш. АБДУМАЖИДОВ
М.А. АБДУЛЛАЕВА
Х.А. АБДУМАДЖИДОВ
Б.З. АБДУСАМАТОВ
М.М. АКБАРОВ
Х.А. АКИЛОВ
М.М. АЛИЕВ
С.Ж. АМИНОВ
Ш.Э. АМОНОВ
Ш.М. АХМЕДОВ
Ю.М. АХМЕДОВ
С.М. АХМЕДОВА
Т.А. АСКАРОВ
М.А. АРТИКОВА
Ж.Б. БЕКНАЗАРОВ (главный редактор)
Е.А. БЕРДИЕВ
Б.Т. БУЗРУКОВ
Р.К. ДАДАБАЕВА
М.Н. ДАМИНОВА
К.А. ДЕХКОНОВ
Э.С. ДЖУМАБАЕВ
А.А. ДЖАЛИЛОВ
Н.Н. ЗОЛотова
А.Ш. ИНОЯТОВ
С. ИНДАМИНОВ
А.И. ИСКАНДАРОВ
А.С. ИЛЪЯСОВ
Э.Э. КОБИЛОВ
А.М. МАННАНОВ
Д.М. МУСАЕВА
Т.С. МУСАЕВ
М.Р. МИРЗОЕВА
Ф.Г. НАЗИРОВ
Н.А. НУРАЛИЕВА
Ф.С. ОРИПОВ
Б.Т. РАХИМОВ
Х.А. РАСУЛОВ
Ш.И. РУЗИЕВ
С.А. РУЗИБОВ
С.А. ГАФФОРОВ
С.Т. ШАТМАНОВ (Кыргызстан)
Ж.Б. САТТАРОВ
Б.Б. САФОВ (отв. редактор)
И.А. САТИВАЛДИЕВА
Ш.Т. САЛИМОВ
Д.И. ТУКСАНОВА
М.М. ТАДЖИЕВ
А.Ж. ХАМРАЕВ
Д.А. ХАСАНОВА
А.М. ШАМСИЕВ
А.К. ШАДМАНОВ
Н.Ж. ЭРМАТОВ
Б.Б. ЕРГАШЕВ
Н.Ш. ЕРГАШЕВ
И.Р. ЮЛДАШЕВ
Д.Х. ЮЛДАШЕВА
А.С. ЮСУПОВ
Ш.Ш. ЯРИКУЛОВ
М.Ш. ХАКИМОВ
Д.О. ИВАНОВ (Россия)
К.А. ЕГЕЗАРЯН (Россия)
DONG JINCHENG (Китай)
КУЗАКОВ В.Е. (Россия)
Я. МЕЙЕРНИК (Словакия)
В.А. МИТИШ (Россия)
В.И. ПРИМАКОВ (Беларусь)
О.В. ПЕШИКОВ (Россия)
А.А. ПОТАПОВ (Россия)
А.А. ТЕПЛОВ (Россия)
Т.Ш. ШАРМАНОВ (Казахстан)
А.А. ЩЕГОЛОВ (Россия)
С.Н. ГУСЕЙНОВА (Азербайджан)
Prof. Dr. KURBANHAN MUSLUMOV (Azerbaijan)
Prof. Dr. DENIZ UYAK (Germany)

ТИББИЁТДА ЯНГИ КУН НОВЫЙ ДЕНЬ В МЕДИЦИНЕ NEW DAY IN MEDICINE

*Илмий-рефератив, маънавий-маърифий журнал
Научно-реферативный,
духовно-просветительский журнал*

УЧРЕДИТЕЛИ:

**БУХАРСКИЙ ГОСУДАРСТВЕННЫЙ
МЕДИЦИНСКИЙ ИНСТИТУТ
ООО «ТИББИЁТДА ЯНГИ КУН»**

Национальный медицинский
исследовательский центр хирургии имени
А.В. Вишневского является генеральным
научно-практическим
консультантом редакции

Журнал был включен в список журнальных
изданий, рецензируемых Высшей
Аттестационной Комиссией
Республики Узбекистан
(Протокол № 201/03 от 30.12.2013 г.)

РЕДАКЦИОННЫЙ СОВЕТ:

М.М. АБДУРАХМАНОВ (Бухара)
Г.Ж. ЖАРЫЛКАСЫНОВА (Бухара)
А.Ш. ИНОЯТОВ (Ташкент)
Г.А. ИХТИЁРОВА (Бухара)
Ш.И. КАРИМОВ (Ташкент)
У.К. КАЮМОВ (Тошкент)
Ш.И. НАВРУЗОВА (Бухара)
А.А. НОСИРОВ (Ташкент)
А.Р. ОБЛОКУЛОВ (Бухара)
Б.Т. ОДИЛОВА (Ташкент)
Ш.Т. УРАКОВ (Бухара)

11 (73)

2024

ноябрь

www.bsmi.uz

<https://newdaymedicine.com> E:

ndmuz@mail.ru

Тел: +99890 8061882

Received: 20.10.2024, Accepted: 02.11.2024, Published: 10.11.2024

UDK 616.12-008.318.1

THE ROLE OF PREDICTORS IN THE FORMATION OF THROMBOSIS IN ATRIAL FIBRILLATION (review article)

Rizaeva M.J. <https://orcid.org/0009-0008-6649-4708>

Bukhara State Medical Institute named after Abu Ali ibn Sina, Uzbekistan, Bukhara, st. A. Navoi. 1

Tel: +998 (65) 223-00-50 e-mail: info@bsmi.uz

Republican Scientific Center for Emergency Medical Care, Bukhara branch.

✓ Resume

Atrial fibrillation (AF) is one of the unfavorable diseases of cardiology, because five times increases the risk of thromboembolic complications (TEC). AF is associated with a number of complications, such as cardioembolic variant of ischemic stroke (IS), worsens the quality of life, reduces exercise tolerance and increases the risk of death rate. A significant contribution to the formation of the pathogenesis of cardiac arrhythmias is played by factors associated with remodeling of the heart chambers and intracardiac hemodynamics.

Key words: atrial fibrillation, arrhythmia, coronary heart disease, remodeling.

РОЛЬ ПРЕДИКТОРОВ К ФОРМИРОВАНИЮ ТРОМБОЗА ПРИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ (обзорная статья)

Ризаева М.Ж. <https://orcid.org/0009-0008-6649-4708>

Бухарский государственный медицинский институт имени Абу Али ибн Сины, Узбекистан, г.

Бухара, ул. А. Навои. 1 Тел: +998 (65) 223-00-50 e-mail: info@bsmi.uz

Республиканский научный центр экстренной медицинской помощи, Бухарский филиал.

✓ Резюме

Фибрилляция предсердий (ФП) одна из неблагоприятных болезней кардиологии, т.к. пятикратно увеличивает риск тромбозмболических осложнений (ТЭО). ФП ассоциируется с рядом осложнений, например, кардиоэмболический вариант ишемического инсульта (ИИ), ухудшает качество жизни, снижает переносимость физических нагрузок и увеличивает риск смертности. Существенный вклад на формирование патогенеза нарушения ритма сердца играют факторы, связанные с ремоделированием камер сердца и внутрисердечной гемодинамикой.

Ключевые слова: фибрилляция предсердий, аритмия, ишемическая болезнь сердца, ремоделирование.

ATRIYAL FIBRILATSIYADA TROMBOZNING SHAKLLANISHI UCHUN BASHORAT QILUVCHILARNING ROLI (adabiyotlar sharhi)

Rizaeva M.J. <https://orcid.org/0009-0008-6649-4708>

Abu Ali ibn Sino nomidagi Buxoro davlat tibbiyot instituti, O'zbekiston, Buxoro, st. A. Navoiy. 1 Tel:

+998 (65) 223-00-50 e-mail: info@bsmi.uz

Respublika shoshilinch tibbiy yordam ilmiy markazi, Buxoro filiali.

✓ Rezyume

Qayta boshlash. Atrialy fibrilatsiya (AF) kardiologiyaning noqulay kasalliklaridan biridir, chunki tromboembolik asoratlar (TEC) xavfini besh baravar oshiradi. AF ishemik insultning (IS) kardioembolik varianti kabi bir qator asoratlar bilan bog'liq bo'lib, hayot sifatini yomonlashtiradi, jismoniy mashqlar tolerantligini pasaytiradi va o'lim xavfini oshiradi. Yurak aritmiyalarining patogenezi shakllantirishga yurak bo'limlari va intrakardiyak gemodinamikani qayta qurish bilan bog'liq bo'lgan omillar muhim hissa qo'shadi.

Kalit so'zlar: atrialy fibrilatsiya, aritmiya, yurak tomirlari kasalligi, remodeling.

Relevance

Atrial fibrillation as an outcome of most cardiovascular diseases, with excessively rapid contractions of the atria. As a result, the efficiency of the heart's pumping function decreases, which leads to a violation of the coordination of cardiac activity. The literature review reveals the clinical significance of determining the severity of the condition of patients with atrial fibrillation complicated by heart failure. According to the World Health Organization (WHO), AF affects about 33.5 million people worldwide, and this figure continues to grow.

The purpose of the study: to identify early clinical predictors in the formation of atrial fibrillation based on the latest research from scientific journals over the past 10 years.

Introduction. According to the World Health Organization (WHO), AF affects about 33.5 million people worldwide, and this figure continues to rise. AF is a significant public health problem based on its high prevalence, complexity of diagnosis and treatment, and high medical costs and lost productivity. Despite improvements in diagnostic and therapeutic methods, AF remains a serious threat to the health and quality of life of patients. Thus, the statistics of Chatterjee S, et al. (2014) showed that LV mass is a factor in the onset of AF [3].

Zaigraev I.A. and a colleague (2019) used laboratory parameters to predict the presence of a thrombus in the left atrium (LA) and/or its appendage (aLA). Scientists have found a relationship between the presence of a thrombus in the LA / aLA of the blood group, peripheral blood parameters, blood levels of brain natriuretic peptide, homocysteine, asymmetric D-methylarginine, uric acid and D-dimer. On the part of the data obtained during transthoracic echocardiography, these are the mass index of the myocardium of the left ventricle, the volume index of the left atrium, the ratio of LVEF / left atrial volume index, the E / e' ratio, the peak systolic deformation of the left atrium [4].

Kornelyuk I.V. and a number of authors have established the effect of a combination of LA dilatation and a decrease in LV EF on the risk of LAA thrombosis. An increase in the anterior-posterior LA size of more than 42 mm with a decrease in LV EF less than 50% increases the risk of detecting a thrombus in the LAA in patients with persistent AF. Thus, to predict the development of thrombosis of the LAA, it is necessary to take into account the size of the LA and LV EF, and patients with a high risk of thrombosis of the LAA are recommended to have a mandatory transesophageal echocardiography (TEE) study. When the peak blood flow velocity (PVC) is lower than 0.341 m/s, a high risk of thrombosis of the LAA is determined, with a PVC greater than or equal to 0.341 m/s, the normal risk of LAA thrombus is determined (sensitivity 77%, specificity 87%) [5].

Transesophageal echocardiography allows not only to identify the presence of a thrombus, but also to assess the features of blood flow in the LAA. In the study of Kornelyuk I.V. the influence of thrombus formation in the LAA was affected by the rate of its emptying, the decrease in PVC to 0.341 m/s, which can be assumed to increase the risk of thrombosis of the LAA. Research data of Kornelyuk I.V. coincides with the results of the SPAF III study, which proved the effect of PSK on the risk of thrombosis in the LAA: where in patients with AF, who had a blood ejection velocity from the LAA of less than 0.2 m/s, a thrombus in the LAA was more often depicted [6], and in the case of Kornelyuk I.V. this threshold turned out to be higher and amounted to 0.341 m/s. [5].

In his study Kornelyuk I.V. during TEE revealed another predictor for the formation of thrombosis in the LAA, this is a decrease in PVC less than 0.341 m/s.

Kharkova N.Yu. (2021) et al. studied patients living in the Far North. During the examination, it turned out that in the selected category of patients, the frequency of detection of LAA thrombosis is 2 times higher due to an increase in the size of the atria, the right ventricle and a low ejection fraction of the left ventricle (LV) [7].

Comparative evaluation of EchoCG data showed that patients with LAA thrombus had more pronounced structural and functional changes in the heart, namely, an increase in the mass index of the left ventricular myocardium and a persistent form of AF [7].

Hasnulin V.I. (2016), Shurkevich NP (2015) and a number of co-authors argue that in the North, in adverse climatic conditions, arterial hypertension is accompanied by the onset of metabolic syndrome, the elastic properties of the vessel wall worsen and kidney damage [8,9].

Described in the works of Hindricks G (EACTS, 2020) and Zaigraev IA (2019) on the presented

cardiovascular risk factors with the development of AF, is currently well studied, and according to research results, these factors, inducing AF, are involved in the pathogenesis of thrombosis in LAA [1,2].

Khorkova N. Yu. managed to identify 2 independent predictors of LAA thrombosis — left ventricular myocardial mass index (LVMI) and persistent AF [7], and irrespective of the region of residence - ischemic heart disease (IHD), persistent form of AF, LA diameter >43 mm and the presence of concentric or eccentric LV hypertrophy [7].

LV hypertrophy is a prognostically unfavorable risk factor for cardiovascular complications [7]. According to Shenasa M, et al. (2015), the cause of the development of LV hypertrophy is not only arterial hypertension (AH), but also obesity, metabolic syndrome, and environmental factors [10], and according to Hasnulin VI (2016), Shurkevich NP (2015), Zapesochaya IL, et al. (2013) the climatic factor on the inhabitants of the Far North is accompanied by a more severe course of AH, gives rise to the process of early remodeling of the heart chambers, thereby contributing to damage to target organs, primarily the left ventricle [8,9,11].

According to Khorkova NYu (2020), LV hypertrophy, due to pressure overload, is accompanied by a gradual dilatation of the heart cavities, incl. LP, leading to an increase in intra-atrial pressure, a violation of the contractile function of the LA, the formation of atrial stunning with parietal blood stasis in them [7]. Boyd AC, et al. (2013) also found that an increase in LV MMI is one of the strongest predictors of LAA thrombosis in patients with persistent AF (the area under the ROC curve was 0.98 [12], что согласуется с результатами исследования Хорьковой Н.Ю., при повышении ИММ ЛЖ на 1 г/м² вероятность развития тромбоза УЛП возрастает на 2,9% [7].

Brain natriuretic peptide (BNP) is a neurohormone secreted by cardiomyocytes, the intensity of which is directly dependent on the pressure in the heart cavities. Hong-ling Yang et al., in a systematic review and a 2-year prospective study, diagnosed LAA cardiomyocytes as the main source of BNP. [13, 14].

There have been similar reports that BNP is an independent predictor of LA/sLA thrombosis. For example, a Japanese retrospective study observed 559 patients with prolonged paroxysmal non-valvular AF who took anticoagulant therapy before cardioversion for 3 weeks, while using TEE revealed 15 patients with LAA thrombus and amounted to 2.7% [15]. BNP was higher with a thrombus in the LAA. After multivariate analysis, BNP value was independently associated with LAA thrombosis. In a study by Ochiumi Y. et al. 204 patients with non-valvular AF, undergoing TEE before EIT, not taking anticoagulants were included. Scientists have noticed that a high concentration of BNP is a predictor of thrombosis [16]. In the conclusions, take into account the level of BNP as a predictor of the presence of a thrombus in the LA/aLA in non-valvular AF.

According to the 2016 update of the American Society of Echocardiography and the European Association for Cardiovascular Imaging and the 2013 European Society of Hypertension and European Society of Cardiology practice guidelines for the treatment of arterial hypertension, transthoracic echocardiography (TT echocardiography) is a routine method of imaging and assessing the structure and function of the heart, used in clinical practice [17, 18]. During the study period, in patients with AF progression, was found pronounced changes in the local contractility of the LV myocardium in the form of a significant increase in the number of akinesis zones and a decrease in the number of normokinesis zones as compared to those in patients in whom the evolution of the course of arrhythmia was not observed [19].

Conclusions

1. Thus, the predictors of k were a decrease in ejection fraction of less than 50%, mitral regurgitation, diastolic ventricular dysfunction, increased blood pressure and blood viscosity, atrial dilatation, and atrial fibrillation itself.

2. There have been no screening studies on the incidence of LAA thrombosis in AF.

LIST OF REFERENCE:

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.

2. Sohara H., Amitani S., Kurose M., Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation. *Journal of the American College of Cardiology*. 1997;29(1):106-12.
3. Chatterjee S, Bavishi C, Sardar P, et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. // *Am J Cardiol*. 2014;114(7):1049-52. doi:10.1016/j.amjcard.2014.07.015
4. Заиграев И.А., Явелов И.С. Тромбоз левого предсердия и/или его ушка при неклапанной фибрилляции предсердий: частота выявления и клинические факторы риска. // *Атеротромбоз*. 2019;(2):68-79. <https://doi.org/10.21518/2307-1109-2019-2-68-79>
5. Корнелюк И.В., Персидских Ю.А., Рабцевич В.А., Корнелюк О.М. (2015). Выбор антикоагулянтной подготовки к кардиоверсии у пациентов с персистирующей фибрилляцией предсердий с учетом эхокардиографических предикторов тромбоза ушка левого предсердия. // *Медицинские новости*, 2015;1(244):37-40.
6. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation // *Ann. Intern. Med*. 1998;128:639-647.
7. Хорькова Н.Ю., Гизатулина Т.П., Белокурова А.В., Горбатенко Е.А., Ярославская Е.И. (2021). Факторы тромбоэмболического риска и предикторы тромбоза ушка левого предсердия у пациентов крайнего севера с неклапанной фибрилляцией предсердий. // *Российский кардиологический журнал*, 2021;(10):100-106.
8. Hasnulin VI, Voevoda MI, Hasnulin PV, et al. Modern Approach to Arterial Hypertension in the Circumpolar and Arctic Regions. Literature Review. *Ekologiya cheloveka [Human Ecology]*. 2016;3:43-51.
9. Shurkevich NP, Vetoshkin AS, Gapon LI, et al. Chronostructure of blood pressure in shiftworkers in the Arctic polar region. "Arterial Hypertension". 2015;21(5):500-13
10. Shenasa M, Shenasa H, El-Sherif N. Left ventricular hypertrophy and arrhythmogenesis. *Card Electrophysiol Clin*. 2015;7(2):207-20. doi:10.1016/j.ccep.2015.03.017
11. Zapesochная IL, Avtandilov AG. Five-year dynamics of circadian blood pressure profile in Far North workers with arterial hypertension. *Russ J Cardiol*. 2013;(6):48-53.
12. Boyd AC, McKay T, Nasibi S, et al. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. *Eur Heart J Cardiovasc Imaging*. 2013;14(3):269-75. doi:10.1093/ehjci/jes153.
13. Hong-ling Yang, Yong-Ping Lin, Yan Long, Qing-ling Ma, Cheng Zhou. Predicting cardioembolic stroke with the B-type natriuretic peptide test: a systematic review and meta-analysis. *J Stroke Cerebrovasc Dis*. 2014;23(7):1882-1889. doi: 10.1016/j.jstrokecerebrovasdis.2014.02.014.
14. Pant R., Patel M., Garcia-Sayan E., Wassouf M., D'Silva O., Kehoe R.F., Doukky R. Impact of B-type natriuretic peptide level on the risk of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation: a prospective study. *Cardiovasc Ultrasound*. 2015;14:4. doi: 10.1186/s12947-016-0047-6
15. Kawabata M., Goya M., Sasaki T., Maeda S., Shirai Y., Yoshitake T. et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial fibrillation patients during anticoagulation therapy – Warfarin vs. Direct Oral Anticoagulants. *Circ J*. 2017;81(5):645-651. doi: 10.1253/circj.CJ-16-1089
16. Ochiumi Y., Kagawa E., Kato M., Sasaki S., Nakano Y., Itakura K. et al. Usefulness of brain natriuretic peptide for predicting left atrial appendage thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation. *J Arrhythm*. 2015;31:307-312. doi: 10.1016/j.joa.2015.04.002.
17. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2016;17(4):412. doi: 10.1093/ehjci/jew041.
18. Mancia G., Fagard R., Narkiewicz K., Redán J., Zanchetti A., Böhm M. et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. *J Hypertens*. 2013;31(10):1925-1238. doi: 10.1097/ HJH.0b013e328364ca4c.
19. Rizaeva, M. Z. (2022). The clinical course of atrial fibrillation in patients with coronary heart disease. *European journal of molecular medicine*, 2022;2(1).

Entered 20.10.2024